Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lutetium Lu-177 LNC1003
- Development stage
- Phase 1
- Lead developer
- Yantai Lannacheng Biotechnology
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals, Small Molecules
- Administration
- Intravenous
01
Overview
Lutetium Lu-177 LNC1003 (also known as [177Lu]Lu-LNC1003 or 177Lu-PSMA-EB-01) is a novel, clinical-stage, prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT) developed by Yantai Lannacheng Biotechnology (a subsidiary of Yantai Dongcheng Pharmaceutical). The drug consists of a high-affinity PSMA-targeting ligand conjugated to an Evans blue (EB) moiety, which is chelated to the beta-emitting radioisotope lutetium-177 (177Lu). The EB moiety reversibly binds to circulating serum albumin, significantly extending the blood circulation half-life of the radioconjugate. This albumin-binding strategy enhances tumor uptake and retention while reducing renal clearance, potentially allowing for lower therapeutic doses and fewer treatment cycles compared to conventional PSMA-targeted radioligands like 177Lu-PSMA-617. Lutetium Lu-177 LNC1003 is currently being evaluated in Phase 1 clinical trials for the treatment of patients with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC).
- Other names
- 177Lu-LNC1003177Lu-PSMA-EB-01[177Lu]Lu-LNC1003lutetium Lu 177 PSMA-EB-01lutetium Lu 177-LNC1003lutetium Lu 177-labeled PSMA-EB-01
02
Targets
DNAPSMA (Prostate-specific membrane antigen)
Beyond the preview
Go deeper on lutetium Lu-177 LNC1003.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lutetium Lu-177 LNC1003.